Now I have all the calibration data I need. Let me write the final consolidated review.

---

## Summary

The paper proposes HYPOGENEAGENT, an LLM-driven framework that uses the consistency of LLM-generated GO annotations across clusters to guide resolution selection in Perturb-seq data. The method defines Intra-Cluster Similarity (ICS) and Inter-Cluster Distinctiveness (ICD) from LLM hypotheses, then combines them into a Resolution Score (RS) that is maximized when clusters are functionally coherent and mutually exclusive. Stage 1 ablation studies on curated GOBP sets select the best LLM/prompt/embedding configuration (GPT-o3 with hypothesis prompt), and Stage 2 applies this to K562 Perturb-seq data at both gene-expression and perturbation levels, comparing the chosen resolution against silhouette, modularity, and enrichment-based baselines.

## Strengths

1. **Novel formulation of resolution selection via annotation consistency** — The paper defines a Resolution Score (Section 3.4, `RS_k = w·ICS_k + (1−w)·(1−ICD_k)`) that turns the heuristic resolution-tuning problem into a quantifiable optimization over LLM-derived annotation consistency. This closes a gap identified in the related work: prior LLM-based annotation tools (GeneAgent, BioDiscoveryAgent) act after clusters are fixed and do not feed functional information back into clustering.

2. **Systematic Stage 1 ablation for model/prompt selection** — Experiments in Section 4.3 (Figures S1, S2, S3) benchmark multiple LLMs (GPT-4o, GPT-o3, Gemini-2.0-flash, Gemini-2.5-pro, GPT-5), prompt designs (general vs. hypothesis), embedding methods (OpenAI, SapBERT, Nomic AI), and temperature settings on curated GOBP gene sets. This provides a reproducible protocol for selecting the best-performing configuration before deployment, which is a methodological strength absent from prior annotation tools.

3. **Application at two levels of analysis** — The method is applied to both gene-expression clusters (Figure 3) and perturbation clusters (Figure 4) in the same K562 Perturb-seq dataset, selecting distinct resolutions (0.4 and 0.5 respectively) with consistent ICS/ICD trends. This demonstrates versatility across data modalities.

## Weaknesses

### Major

1. **No external, non-circular validation of the chosen resolution.** The paper claims the RS selects "biologically interpretable" granularities, but the evaluation provides no quantitative ground truth against which to compare the chosen resolution. The RS is computed from LLM outputs on the same clusters it is supposed to validate — the method finds a resolution where LLM annotations are self-consistent, but there is no independent evidence that this consistency corresponds to biological correctness. The abstract and conclusion make unsupported claims (e.g., "exhibits alignment with known pathway," "optimum matched known perturbation biology") without specifying what known pathways or perturbation effects are being referenced or how alignment was measured. A concrete benchmark — e.g., a dataset with known cell types or perturbation groupings where ARI/NMI can be computed — is needed to substantiate that RS selects biologically meaningful partitions.

2. **The enrichment analysis comparison is contradictory and selectively interpreted.** Section 4.4.3 applies the same ICS/ICD framework to standard GO enrichment (Fisher exact test) results. The figure caption states that the enrichment-based RS "peaks at 0.7" (Figure 6a), yet the paper dismisses this by saying "consider the reasonability of cluster numbers we expected, so the selected resolution can be 0.5 or 0.4, which is consistent." This is not a validation — it is discarding the actual optimum of the baseline to force alignment with the method's choice. If enrichment-based RS were a reliable biology-aware metric, its own optimum (0.7) should be explained, not overridden by subjective "reasonability" expectations.

3. **Unsubstantiated superiority claims over traditional metrics.** The paper states that RS "recovers known perturbation effects better than modularity and silhouette criteria" (abstract) and "exceeded traditional metrics such as modularity, silhouette score and functional enrichment analysis" (Section 4.4.3 summary). However, no head-to-head quantitative comparison is performed — e.g., how many known marker genes are enriched in the RS-chosen clusters versus the silhouette-optimal or modularity-optimal clusters. The comparison is limited to showing that each traditional metric peaks at a different resolution, without establishing that the RS-chosen resolution is biologically better.

### Minor

1. **"Calibrated confidence scores" is misleading.** The paper repeatedly refers to the LLM's outputs as having "calibrated confidence scores" (abstract, Sections 3.3, 3.4, 4.2), but no calibration procedure (e.g., Platt scaling, temperature scaling) is described. The paper simply uses the LLM's raw confidence outputs. While Section 4.3 shows that GPT-o3's confidence correlates with cosine similarity to ground truth on curated sets, this is a correlation, not a calibration. The terminology should be adjusted.

2. **The weight w is chosen on the same data with limited sensitivity analysis.** The RS uses `w = 1/3`, chosen via "a small grid search" on the same K562 data. The paper acknowledges in Figure S5 that changing w can shift the optimal resolution for some clusters. Without a held-out validation or a principled criterion for selecting w, the objectivity of the RS is somewhat undermined.

### Trivial

None.

## Nice-to-Haves

- Validate the LLM's annotations on a handful of real cluster gene signatures (e.g., from resolution 0.4) by comparing to standard enrichment results or expert judgment, to confirm that the LLM's hypotheses are biologically accurate on the actual noisy cluster data, not just on clean curated GOBP sets.
- Report the computational cost (number of LLM calls, API cost, wall-clock time) for practical adoption.
- Use w = 0.5 (equal weight) or show that the ranking of resolutions is stable across a range of w values.

## Removed Points

These points were flagged by the harsh critic but are removed or downgraded after cross-checking against the paper:

- **The claim that RS is "circular" because it uses LLM outputs** (Critic Issue #1, part). The RS measures annotation *consistency* (self-coherence within and across clusters), not absolute accuracy against ground truth. This is a valid metric for its stated purpose. However, the broader point that there is no external biological validation stands and is retained as Major Weakness #1.
- **"Stage 1 validation does not guarantee Stage 2 reliability"** (Critic Issue #4). This is a generic concern applicable to any method that transfers from clean benchmarks to real data. The paper does apply Stage 2 to real data and acknowledges limitations. The concern is not specific enough to constitute a distinct weakness.
- **"The weight w sensitivity analysis raises doubts"** — Downgraded to Minor. The paper acknowledges the sensitivity and notes "stable ordering of resolutions across data sets." The grid search is a reasonable approach for a hyperparameter; the issue is not fatal.
- **Strength Finder's claim about "Empirical alignment with traditional biology-aware metrics"** — Partially removed. The enrichment comparison is contradictory (see Major Weakness #2), so this claimed strength conflicts with a verified weakness.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. **Add a ground-truth validation experiment.** Use a Perturb-seq or scRNA-seq dataset with known cell-type labels or known perturbation groupings (e.g., different perturbations targeting the same pathway). Compute standard clustering metrics (ARI, NMI, enrichment of known markers) at the RS-chosen resolution and compare against the resolution chosen by silhouette, modularity, and enrichment. This directly tests whether RS selects biologically meaningful partitions.

2. **Reconcile or reframe the enrichment comparison.** Either explain why the enrichment-based RS peaks at 0.7 rather than 0.4/0.5, or present the enrichment results as a separate baseline rather than as a validation of HypoGeneAgent's choice. Simply discarding the 0.7 peak based on "reasonability" undermines the paper's objectivity claims.

3. **Remove or substantiate the "known pathway" claims.** Either provide concrete evidence (e.g., specific GO terms or pathways that are enriched in RS-chosen clusters but not in alternative resolutions) or remove the claims from the abstract and conclusion.

4. **Replace "calibrated confidence scores" with "raw confidence scores"** or "confidence scores" and describe the correlation analysis accurately.

---

## Score and Decision

**Calibration anchor summary:**

| Anchor | Path | Avg Score | Round | Comparison |
|---|---|---|---|---|
| BioDiscoveryAgent | HAwZGLcye3.md | 6.40 | 1 | Stronger paper with clear quantitative benchmarks (21% improvement, 6 datasets). HypoGeneAgent is notably weaker in validation rigor. |
| PerturbQA/SUMMER | 5WEpbilssv.md | 4.60 | 2 | Mixed reviews (6,3,5,6,3). Has benchmark contribution. HypoGeneAgent is comparable but slightly weaker due to lack of ground truth. |
| ZerOmics | J1xtkJmFY3.md | 4.67 | 1,2 | Rejected for claiming zero-shot without proper validation. Comparable evaluation gap. |
| GenoAgent | v7aeTmfGOu.md | 4.00 | 1,2 | Rejected for insufficient experiments. HypoGeneAgent has clearer methodology but similar validation concerns. |
| LLM4GRN | jLd7OyAD4Y.md | 4.33 | 1,2 | Rejected — similar challenge of no ground truth. Partially addressed via synthetic data. Comparable. |
| scMPT | nUpM7egYFd.md | 3.40 | 1 | Weaker paper about LLMs for single-cell. HypoGeneAgent is clearly stronger. |

**Round 1 bracket:** 3.5–5.5. **Round 2 narrowing:** Placed paper between GenoAgent (4.0) and ZerOmics (4.67), closer to GenoAgent due to the central validation gap not being adequately addressed in the current form.

The paper presents a genuinely novel idea and thorough engineering, but the core validation is insufficient to support the claims of superiority over traditional metrics. The lack of external ground truth, the mishandled enrichment comparison, and the unsupported claims about "known pathway alignment" are significant weaknesses that prevent acceptance in the current form.

**Score:** 4.0  
**Decision:** Reject

MY FINAL SCORE: <score>4.0</score>
MY FINAL DECISION: <decision>Reject</decision>